Search Results

Genetown

VeroScience Presents New Pipeline Data for Metabolic Disease Therapies at 2019 American Diabetes Association Meeting

VeroScience LLC, presented six preclinical studies aimed at new therapeutic approaches for obesity, prediabetes, type 2 diabetes, and Nonalcoholic Fatty Liver Disease/ Nonalcoholic Steatohepatitis (NAFLD/NASH) at the American Diabetes Association’s 79th Scientific Sessions in San Francisco, Calif. on June 9, 2019.

June 9, 2019

·

2 min read

Pharm Country

VeroScience Release: Two Peer-Reviewed Studies Focusing On Unique Therapeutic Impact Of Veroscience’s Cycloset Recently Published In Journal Of Diabetes Research

June 15, 2015

·

5 min read

Pharm Country

Published Review Paper From VeroScience Delineates 50 Years Of Research Linking Circadian Rhythms With Metabolic Disease

March 16, 2016

·

4 min read

Drug Development

VeroScience Is Pleased To Support Independent Research From The Laboratory Of Dr. Defronzo And Team At UT Health Science Center, San Antonio

June 13, 2016

·

3 min read

Pharm Country

VeroScience Continues To Explore Clinical Benefits Of Circadian Neuroendocrine Resetting Therapy With Six Papers Presented At 2016 American Diabetes Association Scientific Sessions June 10-14

June 13, 2016

·

5 min read

Pharm Country

VeroScience Continues Clinical Evaluation of Bromocriptine-QR (Cycloset) And Neurophysiological Investigations Of Brain Dopamine Regulation Of Metabolism With Eight Papers Presented At The 2015 American Diabetes Association Conference

June 8, 2015

·

4 min read

Biotech Beach

Santarus Inc. and VeroScience Announce CYCLOSET (bromocriptine mesylate) Data Presentations at the American Diabetes Association Meeting

June 21, 2013

·

1 min read

Drug Development

Santarus Inc. and VeroScience Announce Publication of Positive Data From Pivotal CYCLOSET® (bromocriptine mesylate) Efficacy Study

January 23, 2013

·

1 min read

Drug Development

Santarus Inc. and VeroScience Announce Publication of American Association of Clinical Endocrinologists Expert Panel Recommendations for CYCLOSET® (bromocriptine mesylate) for the Management of Type 2 Diabetes

March 6, 2013

·

1 min read

FDA

VeroScience Announces FDA Approval of Cycloset for Treatment of Type 2 Diabetes

May 6, 2009

·

5 min read